Shattuck Labs (NASDAQ: STTK) has announced data from its Phase 1 trial evaluating the safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamics, and immunogenicity of SL-325, its lead DR3 blocking antibody candidate.
In a statement, Taylor Schreiber, MD, PhD, CEO of Shattuck, commented, “SL-325 is now the first antibody that blocks the receptor for TL1A, known as DR3, to generate human clinical data. The profile of SL-325 is highly encouraging, including a potentially best-in-mechanism immunogenicity profile, saturation of DR3 at low doses of SL-325, and durable inhibition of TL1A binding for months after a single dose.”
Dr. Schreiber added, “These data indicate that blocking DR3 with SL-325, or with our DR3 by IL-23 receptor blocking bispecific antibody candidate, SL-846, may substantially improve upon the efficacy shown to date with the TL1A inhibitor class, providing an opportunity to maximize potential efficacy for TL1A blockade in IBD and beyond.”
